CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer

Phase 1 Completed 5 enrolled Roger Williams Medical Center Sorrento Therapeutics, Inc. · collab University of Colorado, Denver · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, fixed dose, phase Ib trial of anti-CEA CAR-T cell infusions delivered via the hepatic artery or splenic vein using the Surefire Infusion System (SIS) for patients with CEA-expressing liver metastases or pancreas cancer.

Timeline

Start: 2017-02-01
Primary completion: 2018-12-31
Completion: 2021-09-17

Publications

Katz SC, Moody AE, Guha P, Hardaway JC, Prince E, LaPorte J, Stancu M, Slansky JE, Jordan KR, Schulick RD, Knight R, Saied A, Armenio V, Junghans RP. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery. J Immunother Cancer. 2020 Aug;8(2):e001097. doi: 10.1136/jitc-2020-001097.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anti-CEA-CAR T	Cell therapy	—	Other

Indications

No indication recorded.